Scilex Holding Company
Index- P/E60.71 EPS (ttm)0.13 Insider Own96.20% Shs Outstand145.81M Perf Week4.61%
Market Cap1.06B Forward P/E- EPS next Y- Insider Trans0.00% Shs Float82.99M Perf Month-9.08%
Income1.80M PEG- EPS next Q- Inst Own9.20% Short Float / Ratio1.21% / 2.59 Perf Quarter120.92%
Sales34.38M P/S30.82 EPS this Y- Inst Trans-10.88% Short Interest1.00M Perf Half Y-25.49%
Book/sh6.78 P/B1.14 EPS next Y- ROA1.30% Target Price- Perf Year-23.81%
Cash/sh0.00 P/C- EPS next 5Y- ROE1.60% 52W Range2.87 - 11.69 Perf YTD93.23%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-34.05% Beta-
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin- 52W Low168.64% ATR0.78
Employees2 Current Ratio0.20 Sales Q/Q36.70% Oper. Margin- RSI (14)48.04 Volatility5.76% 10.45%
OptionableNo Debt/Eq0.00 EPS Q/Q88.10% Profit Margin- Rel Volume0.51 Prev Close7.66
ShortableYes LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume385.97K Price7.71
Recom- SMA20-3.66% SMA50-6.51% SMA200-10.57% Volume197,600 Change0.65%
Mar-27-23 09:00AM
Mar-21-23 09:00AM
Mar-08-23 10:13AM
Feb-27-23 09:00AM
Feb-18-23 08:37PM
03:47PM Loading…
Feb-17-23 03:47PM
Feb-16-23 02:40PM
Feb-13-23 03:46PM
Feb-04-23 10:48PM
Feb-03-23 08:59PM
Feb-02-23 01:15PM
Jan-20-23 10:24AM
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.